Feedback / Questions
SGT-212 - Solid BioSci
https://www.globenewswire.com/news-release/2026/01/12/3217367/0/en/Solid-Biosciences-Receives-FDA-Orphan-Drug-Designation-for-SGT-212-Dual-Route-Gene-Therapy-for-the-Treatment-of-Friedreich-s-Ataxia.html
Jan 12, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next